Valortim((R)) Findings Presented
Dr. Alan Cross, Professor of Medicine and Dr. Subhendu Basu, Assistant Professor of Medicine, University of Maryland School of Medicine, presented data in a poster entitled, "Mechanisms of an anti-PA Antibody (Valortim((R))) that Mediate Protection Against B. Anthracis Infection." The aim of the studies was to determine if the protection against anthrax infection provided by Valortim((R)) was mediated by the immune system.
Study investigators challenged mice with an impaired innate immune system with B.anthracis, with and without Valortim((R)). Their results demonstrated that Valortim((R)) conferred protection to the mice.
In a separate study, mice that lacked an adaptive immune system (devoid of T and B cells) were challenged to establish the role of the cellular immune response in Valortim((R))-mediated protection. Results showed that Valortim((R)) protected these mice at an early time point, post lethal B. anthracis challenge. Study results therefore showed that mice with both impaired adaptive or innate immune responses were protected by Valortim((R)) from a B. anthracis challenge.
Dr. Cross' team concluded that Valortim((R)) supports the ability of innate and adaptive immune responses to control B. anthracis infection. Previous studies have also suggested that Valortim((R)) may play a direct role in killing B. anthracis.
Dr. Cross remarked, "These new data, which augment results from our earlier studies, further highlight the potentially unique activity of Valortim((R)), given its ability to apparently kill B. anthracis, as well as support the immune system's response to anthrax infection."
The work reported by Dr. Cross is supported by the Maryland Industrial Partnerships Program (MIPS). The MIPS pro
|SOURCE PharmAthene, Inc.|
Copyright©2009 PR Newswire.
All rights reserved